SS-31 vs MOTS-c: Two Mitochondrial Peptides, Compared Side by Side

SS-31 is a tetrapeptide, four amino acids in an alternating aromatic and positively charged pattern. That pattern lets it cross cell membranes and concentrate on the inner mitochondrial membrane without a transporter, and without depending on the membrane's electrical potential, so it still reaches mitochondria that are struggling. It was developed by Hazel Szeto and Peter Schiller, which is where the SS comes from. Its development code was MTP-131 and its generic name is elamipretide. All three names are the same molecule. The full reference is at what is SS-31.

• Binding cardiolipin. A 2013 paper in the Journal of the American Society of Nephrology reported high-affinity binding to cardiolipin, a lipid found almost only in the inner mitochondrial membrane, where it holds the membrane's folds (the cristae) in shape. In rat kidneys deprived of blood flow, pre-treatment protected the cristae and prevented mitochondrial swelling.
• Stopping cytochrome c acting as a peroxidase. When cytochrome c binds oxidised cardiolipin it starts damaging the membrane it sits on. The same work reports the SS-31 and cardiolipin complex inhibiting that peroxidase activity while leaving electron transport intact.
• ATP recovery. With the cristae protected, the animal work reports faster recovery of ATP once blood flow returns.

The mechanism detail is from cell and animal studies. The human trials measured function, not mitochondrial biochemistry.

SS-31 has more human trial data than almost any other compounded peptide. The randomised results were mostly negative on their primary endpoints:

There are no randomised trials of elamipretide in healthy adults, in age-related fatigue, in athletic performance or in any longevity use. The trials used 40 mg a day, and Pepti's typical dose is 0.5 mg, a small fraction of that, prescribed for uses the trials did not test.

MOTS-c is a 16-amino-acid peptide whose gene sits in the mitochondrial genome, inside the gene for the 12S ribosomal RNA, rather than in the cell nucleus. It was identified in a 2015 paper in Cell Metabolism from a group at the University of Southern California, and it belongs to a small family of mitochondrial-derived peptides alongside humanin. It is not a hormone in the classical sense, not a growth hormone secretagogue, not a GLP-1 medication and not a stimulant. The full reference is at what is MOTS-c.

• The folate cycle and AMPK. The 2015 paper reported that MOTS-c slows the folate cycle in cells, a by-product called AICAR builds up, and AICAR activates AMPK, the enzyme cells use as a low-fuel sensor. Skeletal muscle appeared to be the main target.
• Moving into the nucleus. A 2018 Cell Metabolism paper reported that under glucose restriction MOTS-c travels into the nucleus and changes which nuclear genes are switched on.
• Muscle and exercise. A 2021 paper in Nature Communications reported better physical performance in treated mice of several ages, and that in humans a bout of exercise raised the body's own MOTS-c. That human finding is observational.
• Fat tissue and bone. Studies in ovariectomised mice (2016 and 2019) reported less bone loss and more brown-fat activity.

There are no randomised controlled trials of MOTS-c in humans. Human data is observational: the body's own MOTS-c rises with exercise, and one cross-sectional study of 225 people reported lower levels in type 2 diabetes. The closest thing to a treatment trial used a modified analogue called CB4211, a different molecule, in small Phase 1 studies whose results were company announcements rather than a peer-reviewed paper, and that programme did not advance. The weight, glucose and fitness findings are from mice.

SS-31 tends to suit someone whose interest is specifically mitochondrial function and who wants the compound with an actual human trial record, while understanding that the trials enrolled people with diagnosed diseases at 80 times the compounded dose. It is a single-agent vial, not part of any blend, which keeps it simple to judge on its own. Tested athletes may note that elamipretide is not named on the 2026 WADA list, though they should still confirm with their anti-doping organisation.

MOTS-c tends to suit someone whose goal is metabolic and tied to training, since the mechanism is an exercise-signalling pathway and the mouse work tested animals that were exercising. It is more often prescribed inside a blend than alone. It is not an option for anyone in a tested sport: it is on the WADA list at all times, USADA has said it is not eligible for a therapeutic use exemption, and a validated test for it exists.

They work through different described mechanisms, and some prescribers combine them. No trial has tested the combination, so it means two sets of unknowns at once. Starting with one makes it easier to tell what, if anything, is changing. Your physician sets your directions after reviewing your intake.